Patterns of change in cognitive function with anastrozole therapy

Area of Science:

• Oncology
• Neuroscience
• Pharmacology

Background:

• Anastrozole is a common treatment for hormone receptor-positive breast cancer.
• Cognitive side effects are a concern for patients undergoing cancer therapy.
• Understanding the impact of anastrozole on cognition is crucial for patient care.

Purpose of the Study:

• To compare the effects of anastrozole therapy on cognitive function in breast cancer patients.
• To assess cognitive changes over 18 months in women receiving anastrozole with or without chemotherapy.

Main Methods:

• A longitudinal cohort study involving postmenopausal women with early-stage breast cancer.
• Groups included chemotherapy plus anastrozole, anastrozole alone, and a control group.
• Cognitive function was assessed at baseline and at 6, 12, and 18 months post-therapy initiation.

Main Results:

• Anastrozole groups showed poorer executive function compared to controls throughout the study period.
• Initial decline in working memory and concentration was observed within the first 6 months of anastrozole therapy.
• A second decline in working memory and concentration occurred between 12 and 18 months for women receiving anastrozole alone.

Conclusions:

• Breast cancer patients on anastrozole experience impaired executive functioning and cognitive decline.
• Anastrozole therapy is associated with initial and, in some cases, recurring deficits in working memory and concentration.
• Long-term cognitive effects of anastrozole beyond 18 months require further investigation.